Galecto Inc. is a biotechnology company developing novel therapeutics for fibrosis and cancer. With a focus on galectin-3 and lysyl oxidase-like 2, the company aims to transform the lives of patients with these debilitating diseases. Galecto’s clinical pipeline shows promise, making it an interesting company to watch in the evolving field of fibrosis research.
